<DOC>
	<DOC>NCT00290394</DOC>
	<brief_summary>The purpose of this study was to determine the effects of rosiglitazone in normotensive type 2 diabetic patients with regard to its blood-pressure–reducing effects.</brief_summary>
	<brief_title>Ambulatory Blood Pressure Reduction After Rosiglitazone Treatment In Normotensive Type 2 Diabetic Patients</brief_title>
	<detailed_description>The first study to evaluate the effects of troglitazone on blood pressure in humans was published recently, which demonstrated a 5/4 mm Hg reduction in ambulatory blood pressure in 18 nondiabetic obese subjects after 12 weeks’ treatment. Another study in 18 hypertensive subjects with diabetes mellitus showed an 18/12 mm Hg decline in office blood pressure after 8 weeks of treatment.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Blood pressure of patients were in normotensive limits according to the JNC VII Diabetes mellitus treated with oral antidiabetics or diet Any known hypertension, coronary artery disease, congestive hearth failure, renal disease or liver disease Antihypertensive treatment</criteria>
	<gender>All</gender>
	<minimum_age>49 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2004</verification_date>
	<keyword>Blood Pressure,</keyword>
	<keyword>rosiglitazone,Diabetes Mellitus, Type 2,</keyword>
</DOC>